These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 22335953

  • 1. [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
    Han BH, Xiu QY, Wang HM, Shen J, Gu AQ, Luo Y, Bai CX, Guo SL, Liu WC, Zhuang ZX, Zhang Y, Zhao YZ, Jiang LY, Shi CL, Jin B, Zhou JY, Jin XQ.
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):854-9. PubMed ID: 22335953
    [Abstract] [Full Text] [Related]

  • 2. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
    Han B, Xiu Q, Wang H, Shen J, Gu A, Luo Y, Bai C, Guo S, Liu W, Zhuang Z, Zhang Y, Zhao Y, Jiang L, Zhou J, Jin X.
    J Thorac Oncol; 2011 Jun; 6(6):1104-9. PubMed ID: 21532504
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
    Li N, Jin ZL, Liu ZJ, Wang J, Li K.
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
    [Abstract] [Full Text] [Related]

  • 4. [Efficacy and safety of rh-endostatin combined with docetaxel in second-line or intolerant toxicity for first-line treatment in patients with advanced non-small cell lung cancer].
    Wang J, Li K, Sun T, Zhang MJ, Li WL, Yao Q, Liu W, Ding CM, He ZY, Mao WD, Wang HM, Zhang Y, Zhou XL.
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):618-22. PubMed ID: 24314222
    [Abstract] [Full Text] [Related]

  • 5. The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
    Li X, Gu G, Soliman F, Sanders AJ, Wang X, Liu C.
    Chemotherapy; 2018 Aug; 63(4):214-219. PubMed ID: 30347389
    [Abstract] [Full Text] [Related]

  • 6. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
    Lara PN, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G.
    J Clin Oncol; 2011 Aug 01; 29(22):2965-71. PubMed ID: 21709202
    [Abstract] [Full Text] [Related]

  • 7. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis.
    Ge W, Cao DD, Wang HM, Jie FF, Zheng YF, Chen Y.
    Asian Pac J Cancer Prev; 2011 Aug 01; 12(11):2901-7. PubMed ID: 22393961
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
    Kong Q, Wang XY, Jiang RC, Ba Y, Li K.
    Zhonghua Zhong Liu Za Zhi; 2016 Apr 01; 38(4):294-9. PubMed ID: 27087377
    [Abstract] [Full Text] [Related]

  • 9. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
    Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY.
    J Clin Oncol; 2015 Jul 01; 33(19):2197-204. PubMed ID: 26014294
    [Abstract] [Full Text] [Related]

  • 10. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
    Spigel DR, Luft A, Depenbrock H, Ramlau R, Khalil M, Kim JH, Mayo C, Chao GY, Obasaju C, Natale R.
    Clin Lung Cancer; 2017 Sep 01; 18(5):480-488. PubMed ID: 28365238
    [Abstract] [Full Text] [Related]

  • 11. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
    Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L.
    J Clin Oncol; 2010 Jan 01; 28(1):49-55. PubMed ID: 19917841
    [Abstract] [Full Text] [Related]

  • 12. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
    Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR, Woytowitz D.
    J Clin Oncol; 2010 Feb 20; 28(6):911-7. PubMed ID: 20100966
    [Abstract] [Full Text] [Related]

  • 13. Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
    Novello S, Scagliotti GV, Sydorenko O, Vynnychenko I, Volovat C, Schneider CP, Blackhall F, McCoy S, Hei YJ, Spigel DR.
    J Thorac Oncol; 2014 Aug 20; 9(8):1154-61. PubMed ID: 25157768
    [Abstract] [Full Text] [Related]

  • 14. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.
    Lopez-Chavez A, Young T, Fages S, Leon L, Schiller JH, Dowlati A, Brahmer JR, Johnson DH, Sandler A.
    J Thorac Oncol; 2012 Nov 20; 7(11):1707-12. PubMed ID: 23059774
    [Abstract] [Full Text] [Related]

  • 15. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.
    Reck M, Krzakowski M, Chmielowska E, Sebastian M, Hadler D, Fox T, Wang Q, Greenberg J, Beckman RA, von Pawel J.
    Lung Cancer; 2013 Dec 20; 82(3):441-8. PubMed ID: 24148258
    [Abstract] [Full Text] [Related]

  • 16. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
    Paz-Ares L, Bálint B, de Boer RH, van Meerbeeck JP, Wierzbicki R, De Souza P, Galimi F, Haddad V, Sabin T, Hei YJ, Pan Y, Cottrell S, Hsu CP, RamLau R.
    J Thorac Oncol; 2013 Mar 20; 8(3):329-37. PubMed ID: 23370314
    [Abstract] [Full Text] [Related]

  • 17. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis.
    Ge W, Cao DD, Wang HM, Jie FF, Zheng YF, Chen Y.
    Asian Pac J Cancer Prev; 2011 Mar 20; 12(10):2705-11. PubMed ID: 22320978
    [Abstract] [Full Text] [Related]

  • 18. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer.
    Rong B, Yang S, Li W, Zhang W, Ming Z.
    World J Surg Oncol; 2012 Aug 24; 10():170. PubMed ID: 22917490
    [Abstract] [Full Text] [Related]

  • 19. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
    Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, Zhang L, Tamura T, Postmus PE, Jassem J, O'Byrne K, Kopit J, Li M, Tschaika M, Reck M.
    J Clin Oncol; 2017 Oct 20; 35(30):3449-3457. PubMed ID: 28854067
    [Abstract] [Full Text] [Related]

  • 20. Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR.
    Choi YJ, Lee DH, Choi CM, Lee JS, Lee SJ, Ahn JH, Kim SW.
    BMC Cancer; 2015 Oct 22; 15():763. PubMed ID: 26493267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.